Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9231 in Healthy Caucasian Participants
NCT06519981Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-9231 in Central nervous system diseases and vascular disease (2 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Adverse events at Day 8, Vital signs at Day 8 and 4 more. Started Aug 2024; status: completed.
02
Drugs
HRS-9231
03
Conditions
Central nervous system diseasesvascular disease
Beyond the preview
Go deeper on NCT06519981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519981.